Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RNP-002 is a preclinical-stage biomaterial candidate developed by Cellontech (part of Sewon Cellontech's Regenerative Medical System) specifically for bone regeneration. It is designed as a biocompatible scaffold, likely utilizing the company's proprietary bio-collagen (atelocollagen) technology, to provide a three-dimensional structural framework that supports osteoconduction. The material facilitates the migration, attachment, and proliferation of osteogenic cells, thereby promoting the natural healing and mineralization of bone tissue. RNP-002 is intended for surgical implantation into areas of bone loss or injury to restore structural integrity and function as part of a regenerative medicine approach.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RNP-002.